A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Summary

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.

Timeline

Start

2019-09-11

Primary completion

2020-12-17

Completion

2020-12-17

Outcome

Outcome not reported

Stopped (Business): “Terminated based on Sponsor decision due to lot recall of GEBT kits impacting the primary endpoint evaluation for Dose 2 and Dose 3.”

Drugs

Indications